Check out our monthly newsletter and subscribe to keep track of our events and opportunities.
Liv Labs is on a mission to improve women's pelvic health and reduce stress incontinence. Their flagship product, the Pippa, is a soft silicone spring that activates pelvic floor muscles with each step, stretch, or squat. It is a recent honoree of a Fast Company 2025 Innovation by Design award alongside brands like LG, Panasonic, OXO and Google, with the judges loving how Pippa provides breakthrough functionality with elegant simplicity.
Raise status:
Liv Labs' Seed round is targeting an April 2026 close so the time to reach out for more info is now! Reach out to your WeCAN connection(s) for a warm intro.
Website and contact:
Arovia is building a patented nanomaterials platform designed for environments where traditional displays fail. Arovia's flagship products, the Splay and Splay Max, deliver bright, eye‑friendly visuals that are rugged enough for field operations yet portable enough for everyday work. In the R&D pipeline, this same nanomaterial foundation is being developed for future applications in solar panel protection, greenhouse covers, and active camouflage.
Raise status:
Arovia has added additional room to its Seed round given new traction and interest. Reach out to your WeCAN connection(s) for a warm intro.
Website and contact:
Mars Materials is building a low-carbon materials platform that turns captured CO₂ into industrial inputs for products that clean dirty water and strengthen transportation and energy systems. Its flagship product, Hoigen-C, is a drop-in acrylonitrile designed to replace the conventional fossil-based version used in water-treatment polymers and carbon fiber, marking an important step toward cleaner, domestic production of a critical industrial building block.
Raise status:
Watch out for Mars Materials' Seed round coming in 2026.
Website and contact:
TippingPoint Biosciences is an early-stage therapeutic company, spun out of Dr. Geeta Narlikar’s lab at UCSF, with a novel drug discovery platform to identify first-in-class drugs aimed at treating diseases related to dysfunctional DNA packaging (chromatin).
TippingPoint Bio is the first to develop a screening platform to enable direct targeting of the defective chromatin in disease cells without affecting healthy cells. The platform can be applied to multiple disease areas like cancer, neurodegenerative diseases and developmental disorders.
Raise status:
TippingPoint completed an oversubscribed $4.5m seed round in March 2026.
Website and contact: